current and novel treatment approaches for first-line egfr-m nsclc
Published 14 hours ago • 24 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:51
evaluating first-line therapies for egfr-mutated nsclc in 2024
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
6:41
egfr-positive nsclc: treatment at progression
-
20:24
targeted treatment with egfr tkis: front line options
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
4:40
egfr-vegf inhibition for first-line egfr mnsclc treatment
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
1:46
the evolving treatment landscape for nsclc with egfr exon 20 insertion mutations
-
7:35
treatment for patients with egfr nsclc - leading developments & current questions in lung cancer
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
1:18
first-line treatment of metastatic egfr-mutated non-small cell lung cancer
-
4:56
active trial update: egfrm nsclc
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc